


---

# International Organization of MS Nurses

## Symptom Management in MS

Supported by Novartis Pharmaceuticals Corporation




# Goals of Symptom Management

---

- Eliminate or reduce symptoms that impair functional abilities
- Improve quality of life
- Avoid secondary complications
- Use targeted and individualized treatment of symptoms (essential in management of MS)


# Multi-Disciplinary Team Approach

---



# Neurologic Origins

Symptom presentation depends on lesion location



# Primary Symptoms of MS

---

- Vision disturbance
- **\*Altered mobility, weakness**
- **\*Spasticity**
- **\*Tremor**
- Altered sensation
- **\*Bladder and bowel dysfunction**
- **\*Sexual dysfunction**
- Cognitive problems
- Fatigue

**\*Will be  
discussed in  
this presentation**

# Secondary Symptoms of MS

---

- Infections
- Falls
- Skin breakdown
- Pain

# Tertiary Symptoms

---

- **\*Psychosocial issues**
- Job loss
- Loss of intimacy
- Role changes/family disruption
- Social isolation
- Sleep disturbance

**\*Will be discussed  
briefly in this  
presentation**


# Bladder Dysfunction

---

- 70%–80% of persons with MS may experience problems with bladder function
- Symptoms of neurogenic bladder include urgency, frequency, incontinence, hesitancy, incomplete emptying, nocturia
  - Inability to store
  - Inability to empty
  - Combined dysfunction, detrusor sphincter dyssynergia



# Bladder Physiology



- Initial urge 200–300 cc
- Capacity 500+ cc
- Flow rate 15 cc/second
- Voiding Pressure
  - 30–60 cm/women
  - 80 cm/men
- Post-void residual (PVR) negligible

# Common Bladder Symptoms

---

- Urgency
- Frequency
- Hesitancy
- Double voiding
- Involuntary urination
- Nocturia
- Urinary tract infections (UTIs)
- Dysuria

# Bladder Dysfunction

Inability to Store	Inability to Empty	Combination/DSD
<p><b>Symptoms</b></p> <ul style="list-style-type: none"> <li>• Urgency/frequency</li> <li>• Incontinence</li> <li>• PVR &lt;100 mL</li> </ul>	<p><b>Symptoms</b></p> <ul style="list-style-type: none"> <li>• Urgency, hesitancy</li> <li>• Double voiding</li> <li>• Frequency</li> <li>• Incomplete emptying</li> <li>• Nocturia</li> <li>• PVR &gt;100 mL</li> <li>• History of UTI</li> </ul>	<p><b>Symptoms</b></p> <ul style="list-style-type: none"> <li>• Urgency, hesitancy</li> <li>• Double voiding</li> <li>• Incomplete emptying</li> <li>• Dribbling incontinence</li> <li>• Diagnosed by urodynamic studies</li> </ul>

DSD=detrusor sphincter dyssynergia; PVR = post-voiding residual; UTI=urinary tract infection.

Namey MA. In: Halper J, Holland NJ, eds. *Comprehensive Nursing Care in Multiple Sclerosis*. 3rd ed. 2010.

Choi JM, Kim JH. In: Giesser BG. *Primer on Multiple Sclerosis*. 2016.

# Assessment of Bladder Function

---

- Thorough history: patient's main concern
  - Voiding patterns (voiding diary)
  - Fluid intake
- Spontaneous void
- Measurement of PVR
  - Determines the amount retained in the bladder after voluntary emptying
  - Evaluated by bladder ultrasound or catheterization
- Other causes of bladder dysfunction:
  - Urinary tract infections
  - Pelvic floor relaxation in women
  - Benign prostatic hyperplasia in men

PVR=post-void residual.

Namey MA. In: Halper J, Holland NJ, eds. *Comprehensive Nursing Care in Multiple Sclerosis*. 3rd ed. 2010.

Choi JM, Kim JH. In: Giesser BG. *Primer on Multiple Sclerosis*. 2016.

# Treatments: Inability to Store

---

- Limit fluid intake
- Frequent bathroom breaks
- Quick access to bathroom
- Pads or protective undergarments
- Decrease use of bladder irritants (caffeine, aspartame, alcohol)
- Anticholinergic/antimuscarinic agents:
  - Darifenacin (Enablex<sup>®</sup>)
  - Solifenacin succinate (VESIcare<sup>®</sup>)
  - Tolterodine (Detrol<sup>®</sup>/LA),
  - Fesoterodine fumarate (Toviaz<sup>®</sup>)
  - Oxybutynin (Ditropan/XL<sup>®</sup>), oxybutynin transdermal\*
- Beta-3 adrenergic receptor agonists
  - Mirabegron (Myrbetriq<sup>®</sup>)
  - Vibegron (Gemtesa<sup>®</sup>)
- Onabotulinumtoxin A (Botox<sup>®</sup>)

\*First-generation anti-cholinergics with more side effects than other agents.

Namey MA. In: Halper J, Holland NJ, eds. *Comprehensive Nursing Care in Multiple Sclerosis*. 3rd ed. 2010; Sanford M. *Drugs*. 2014;74:1659-1672.

# Treatments: Inability to Empty

---

- Adequate fluid intake
- Structured, timed voidings
- Intermittent catheterization, indwelling catheter, suprapubic catheter
- Alpha blockers
  - Tamsulosin (Flomax®)
  - Doxazosin (Cardura®)
- Anti-spasticity agents/nerve blocks

# What Patients Need to Know

---

- Drink fluids all at once; if you sip, sip, sip you will feel the urge to go often
- Try to void about 1.5–2 hours after you drink
- Stop drinking fluids about 2 hours before bedtime
- Void right before bedtime
- It is not normal to leak urine regardless of one's age, wake up more than once at night to void, or have frequent UTIs
- Symptoms of UTIs
- Effect of UTIs on MS symptoms
- Importance of early treatment of UTIs

# Bowel Dysfunction

---

- Approximately 68% of persons with MS may experience problems with bowel function
- Common symptoms include constipation, diarrhea, incontinence
- Symptoms may be intermittent or constant
- Symptoms can occur at any time in the disease



# Bowel Symptoms in MS

---

- Constipation
  - Slow bowel
  - Medications
  - Impaired motility
  - Induced dehydration due to bladder issues
- Bowel incontinence
  - Diminished sphincter control
  - Hyperreflexic bowel

# Summary: Bowel Dysfunction Management

**Bowel training/dietary modification recommended for all bowel dysfunction, plus...**

## Constipation

- Fluids 1.5–2 quarts/day
- Daily fiber 20–30 grams/day
- Bulk-forming agents
- Stool softeners/stimulants
- Laxatives/enemas
- Suppositories
- Exercise

## Bowel Incontinence

- Identify dietary triggers
- Medications/suppositories
- Bulk-forming agents
- Timed evacuations

# Sexual Dysfunction in MS

---

- Approximately 40%–85% of women with MS
- Approximately 50%–90% of men with MS
- Has significant impact on quality of life
- Common yet often overlooked symptom of MS

# Primary Sexual Dysfunction in MS

---

Men and women can experience difficulties with:

- ↓ Libido
- ↓ Erectile dysfunction/ejaculation
- ↓ Altered genital sensation
- ↓ Frequency/intensity of orgasms
- ↓ Vaginal lubrication/clitoral engorgement
- ↑ Bladder spasticity
- ↑ Depression

# Sexual Dysfunction Management

---

- Exclude metabolic causes (eg, diabetes)
- Management strategies include:
  - Pharmacologic management
  - Treat underlying symptoms/secondary dysfunction
    - Spasticity, fatigue, paresthesias, bladder/bowel issues
  - Adjust medications
  - Positioning, lubrication, assistive devices
  - Lifestyle changes
- Key to successful management is open communication
- Counseling and culturally sensitive support

# Altered Mobility in MS

---

## Common Symptom

- Possible causes:
  - Spasticity
  - Weakness
  - Imbalance
  - Sensory loss
  - Vision changes
  - Peripheral neurological changes
- Risks:
  - Decreased safety (eg, increased risk of falls)
  - Impaired biomechanics
  - Pain
  - Immobility
  - Isolation
  - Reduced quality of life

# Management of Mobility Issues

---

- Rehabilitation therapy (physical and occupational therapy)
- Assistive devices, orthoses, adaptive equipment
- Exercise—deliberate, regular movement
- Medications (ie, trial of dalfampridine “walking pill”)
- Surgery (orthopedic surgery or neurosurgical interventions for spasticity)

Bethoux F et al. In: Rae-Grant AD et al (eds). *Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation*. 2nd ed. 2018;

Bennett SE et al. *Int J MS Care*. 2014;16, Suppl 1:1-40; Bennett SE et al. *Int J MS Care*. 2014;16(Suppl 1):1-11.

# Spasticity in MS

---

- Hypertonicity of muscles “tightness, pulling, tugging, aching”
- Results from demyelination in descending CNS pathways
- Different muscle groups involved depending on lesion location
- Spasticity may increase over time without new CNS lesions
- Results in:
  - Increased resistance to stretch
  - Accentuation of deep tendon reflexes and clonus
  - Uncontrolled flexor responses and extensor spasms
  - Limited mobility
  - Excessive energy expenditure
  - Pain and discomfort

CNS=central nervous system.

Bethoux F et al. In: Rae-Grant AD et al (eds). *Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation*. 2nd ed. 2018



# Modified Ashworth Scale

---

Score	Criteria
0	No increased tone
1	Slight increased tone (catch and release at end of ROM)
1+	Slight increase in tone manifested by a catch followed by min. resistance throughout the remainder of the ROM (less than half the ROM)
2	Marked increase in tone through most of ROM but affected part(s) move easily
3	Considerable increased tone, passive movement difficult
4	Affected part(s) rigid in flexion or extension

ROM=range of movement.

Meseguer-Henarejos AB et al. *Eur J Phys Rehabil Med.* 2018;54:576-590.

# Spasticity Management

## Non-pharmacologic

- Stretching
- Positioning/Posture
- Seating
- Range of motion
- Orthotics
- Physical therapy

## Pharmacologic

- Baclofen
- Tizanidine
- Clonazepam, diazepam
- Gabapentin
- Onabotulinum toxin A
- Cannabis?

## Surgical

- Baclofen pump

Bethoux F et al. In: Rae-Grant AD et al (eds). *Multiple Sclerosis and Related Disorders: Clinical Guide to Diagnosis, Medical Management, and Rehabilitation*. 2nd ed. 2018;

Halper J et al. *Comprehensive Care in Multiple Sclerosis: A Core Curriculum*. 3rd ed. 2022.

# Intrathecal Baclofen (ITB™) Therapy

- Pump infuses drug at programmed rate
- Catheter delivers drug to the intrathecal (subarachnoid) space of the spinal cord
- Programmer allows for precise, easily adjustable dosing



# Tremor in MS

---

- Less common symptom
- Caused by MS lesions in cerebellum and its pathways
- Can affect head, limbs, trunk, eye movements, and speech (dysarthria)
- Titubation-tremor in the head, neck, or trunk
- Difficult to treat and can be embarrassing

# Tremor Management

---

## Non-pharmacologic

- Proximal stability
- Self-care strategies
- Weight-bearing activities
- Weighting (utensils, assistive devices)
- Coordination exercises
- Occupational therapy

## Pharmacologic

- Clonazepam
- Gabapentin
- Primidone
- Propranolol
- Levetiracetam
- Topiramate

## Surgical

- Deep brain stimulation

# Psychosocial Issues

---

- Depression
  - About 50% of patients with MS experience depression at some time
  - Rate is much higher than general population
- Suicide
  - Rates are much higher than general population
- Screen for depression and other mental health problems frequently
- Refer as appropriate for counseling
- Medications: variety of antidepressants are available

# Lifestyle Recommendations for Managing All Symptoms

---

- Education about disease and its symptoms
- Stress management
- Healthy diet
- Regular activity/exercise
- Socialization
- Complementary and alternative therapies (CAM)
- Psychosocial support

# Summary: Symptom Management

---

- Clinical approach to symptom management is what healthcare providers do best and most often
- MS symptoms affect quality of life of individuals with multiple sclerosis
- Left untreated, symptoms may worsen or precipitate other symptoms, producing a cycle of inter-related symptoms
- Nurses listen, respond with care and concern, treat, and make referrals



# Nursing Implications

---

- Symptom management follows the same general rules as disease management
- Diagnose the problem and intervene early
- Identification of symptoms is key
  - Need to confirm the nature of the symptoms and link to MS (MS or not MS)
  - Secondary causes (comorbidities may contribute to symptoms)
- Use multimodal, multidisciplinary management
- Identify interventions (non-pharmacologic and pharmacologic)
- Monitor and adjust treatment plan as needed over time

## Nursing Implications (continued)

---

- Acknowledge that many MS symptoms overlap
- Educate patients regarding role of contributing factors (ie, medications, infections, heat, deconditioning, etc)
- When a symptom is new or suddenly worsens, re-evaluate for contributing factors both internal (disease activity) or external (environmental issues)